重组人干扰素α-1b联合布地奈德雾化对合胞病毒性肺炎患儿睡眠质量和生命质量的影响

The Impact of Recombinant Human Interferonα-1b Combined with Budesonide Nebulization on Sleep Quality and Quality of Life in Children with Cytomegalovirus Pneumonia

目的:观察重组人干扰素α-1b联合布地奈德雾化对小儿呼吸道合胞病毒性肺炎患儿生命质量和睡眠质量的影响。方法:选取2022年3月至2023年10月福建省莆田市第一医院儿科收治的合胞病毒性肺炎患儿90例作为研究对象,按照随机数字表法分为对照组和观察组,每组45例。对照组予以常规方案用药治疗,观察组予以重组人干扰素α-1b联合布地奈德雾化治疗。比较2组患儿睡眠质量、生命质量以及症状改善时间、炎症介质水平变化。结果:治疗后观察组夜间觉醒次数低于对照组,日平均睡眠时间、夜间最长连续睡眠时间均长于对照组(均P<0.05)。观察组咳嗽、咽喉疼痛、胸闷以及发热症状改善时间均短于对照组(均P<0.05)。治疗后2组患儿的世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分均高于本组治疗前(均P<0.05),且观察组治疗后的评分高于对照组(P<0.05)。治疗后2组患儿炎症介质白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平均较本组治疗前降低(均P<0.05),且观察组治疗后各指标水平均低于对照组(均P<0.05)。结论:重组人干扰素α-1b联合布地奈德雾化治疗可以迅速改善合胞病毒性肺炎患儿的临床症状,提升患儿睡眠质量和生命质量。

Objective:To observe the effects of recombinant human interferonα-1b combined with budesonide nebulization on the quality of life and sleep quality in children with respiratory syncytial virus pneumonia.Methods:Ninety children with respiratory syncytial virus pneumonia admitted to the Department of Pediatrics,Putian First Hospital,Fujian Province,from March 2022 to October 2023 were selected as the study subjects.They were randomly divided into a control group and an observation group,with 45 cases in each group.The control group received conventional treatment,while the observation group received treatment with recombinant human interferonα-1b combined with budesonide nebulization.The sleep quality,quality of life,time of symptom improvement,and changes in inflammatory factor levels were compared between the two groups.Results:After treatment,the number of nocturnal awakenings in the observation group was lower than that in the control group,and the average daily sleep time and the longest consecutive sleep time at night were longer than those in the control group(P s<0.05).The time for improvement of cough,sore throat,chest tightness,and fever symptoms in the observation group was shorter than that in the control group(P s<0.05).The World Health Organization Quality of Life-BREF(WHOQOL-BREF)scores of the two groups were higher after treatment than before treatment(P s<0.05),and the scores in the observation group after treatment were higher than those in the control group(P<0.05).After treatment,the levels of inflammatory factors interleukin-6(IL-6),C-reactive protein(CRP),and tumor necrosis factor-α(TNF-α)in both groups were lower than before treatment(P s<0.05),and the levels in the observation group after treatment were lower than those in the control group(P s<0.05).Conclusion:Treatment with recombinant human interferonα-1b combined with budesonide nebulization can quickly improve clinical symptoms,sleep quality,and quality of life in children with respiratory syncytial virus pneumonia.